Zydus receives USFDA EIR for Ankleshwar API facility with ‘No Action Indicated' status
Zydus Lifesciences Limited announced on Wednesday that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility located in Ankleshwar, Gujarat.
The inspection, which was carried out between March 10 and March 14, 2025, has been classified as 'No Action Indicated' (NAI), indicating that the USFDA found no objectionable conditions during its assessment. The inspection is now officially closed, the company confirmed in a press release dated June 11, 2025.
This development is seen as a positive regulatory milestone for Zydus, ensuring continued compliance and uninterrupted operations at its active pharmaceutical ingredient (API) facility.
The company has disclosed the update under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and has submitted the information to both BSE (Code: 532321) and NSE (Symbol: Zyduslife).
Shares of Zydus Lifesciences may react to this regulatory update when markets open.
News desk at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
8 hours ago
- Entrepreneur
Yali Capital Closes ₹893 Crore Deep Tech Fund
The fund will invest in both early-stage (Seed, Series A) and late-stage (Series D and beyond) startups, with a strong emphasis on deep-tech domains such as semiconductors, artificial intelligence, robotics, genomics, aerospace/surveillance, and smart manufacturing. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Yali Capital, a SEBI-registered Category II Alternative Investment Fund (AIF), has announced the successful close of its maiden deep tech-focused fund at INR 893 crore (approximately USD 104 million), significantly surpassing its initial target of INR 500 crore and a INR 310 crore greenshoe option. The fund will invest in both early-stage (Seed, Series A) and late-stage (Series D and beyond) startups, with a strong emphasis on deep-tech domains such as semiconductors, artificial intelligence, robotics, genomics, aerospace/surveillance, and smart manufacturing. Lip-Bu Tan, veteran investor and advisor to Yali Capital, said, "I strongly believe in India's deep tech capabilities. It is heartening to see the government, global corporations, and successful entrepreneurs come together to back Yali's deep tech thesis. I look forward to supporting Yali in laying the foundation for India's deep tech ecosystem." To attract a global investor base, Yali Capital operates through a dual-structure setup, comprising the SEBI-regulated AIF and a feeder vehicle based in GIFT City. The firm has already made five investments, covering sectors like chip design and AI, and aims to expand its portfolio to eight companies by the end of the year. Yali's Limited Partners (LPs) span a diverse and influential set of backers, including: Infosys, Qualcomm Ventures, Tata AIG; Funds of Funds such as DPIIT's Fund of Funds for Startups (managed by SIDBI), Self-Reliant India Fund, Evolvence, and Singularity FOF; Prominent Individuals such as Kris Gopalakrishnan (Pratithi), Gopal Srinivasan (TVS Capital), Vallabh Bhansali (ENAM), Utpal Sheth (RARE Enterprises), Vishal Kampani (JM Financial), Sanjay Nayak (Tejas Networks), Nambi Seshadri (ex-CTO, Broadcom Wireless), and C. Srinivasan (Cosmic Circuits). Mathew Cyriac, General Partner at Yali Capital, stated: "Nearly a third of our fund will be invested in late-stage deep tech companies. India has a real opportunity to build globally competitive public companies in this space. We are grateful to the global investor community for backing our vision." Yali has already disclosed investments in companies including C2I Semiconductor, 4basecare, and Perceptyne. The fund intends to continue deploying capital actively over the next four years. Ganapathy Subramaniam, Founding Managing Partner of Yali Capital, added, "We are deeply grateful for the overwhelming support from the global tech community. Two-thirds of the fund will be deployed in early-stage deep tech startups. We firmly believe in India's deep tech potential and are committed to backing visionary founders with patient capital."
Business Upturn
12 hours ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
14 hours ago
- Business Upturn
Concord Biotech successfully completes Russian GMP inspection at Dholka API facility
Concord Biotech is pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22, 2025, to July 25, 2025. In the exchagne filings, the company shared, 'We are pleased to announce the successful completion of the Russian GMP (Good Manufacturing Practice) inspection at our Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. The inspection was conducted from July 22' 2025 to July 25' 2025.' This achievement underscores the company's commitment to upholding the highest standards of quality, safety, and regulatory compliance across all areas of its operations. It also reflects Concord Biotech's continued focus on meeting the rigorous requirements of global regulatory authorities. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
